|

Camrelizumab Plus Chemotherapy Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Shandong Cancer Hospital and Institute1
  • Fudan University1

Indications

  • Cancer2
  • Resectable Lung Non-Small Cell Carcinoma1
  • TNBC - Triple-Negative Breast Cancer1
  • Biomarkers / Blood1
  • Immunotherapy1

Other2 trials

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Phase 3
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.